Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.
复制标题
DOI：
10.1186/s40364-021-00312-w
复制
发表时间：
2021-07-22
影响因子：
11.1
通讯作者：
Chen Z
中科院分区：
文献类型：
--
作者：
Chen W;Shen L;Jiang J;Zhang L;Zhang Z;Pan J;Ni C;Chen Z
肿瘤血管生成诱导局部缺氧并招募免疫抑制细胞，而缺氧随后促进肿瘤血管生成。免疫治疗的效果取决于肿瘤浸润性免疫细胞（TIICs）的积累和活性。抗血管生成治疗可改善局部灌注，缓解肿瘤微环境（TME）缺氧，逆转免疫抑制状态。联合抗血管生成疗法和免疫疗法可能是治疗乳腺癌的一个有希望的选择。本文讨论了乳腺癌TME的免疫抑制特性，并概述了肿瘤血管与免疫系统的相互作用。抗血管生成治疗联合免疫治疗可阻断肿瘤异常血管-免疫抑制串扰，增加效应免疫细胞浸润，提高免疫治疗效果，降低免疫相关不良事件的发生风险。此外，我们总结了抗血管生成治疗与免疫治疗联合治疗的临床前研究和正在进行的临床研究，讨论了其潜在的机制，并对未来的发展提出了展望。抗血管生成治疗与免疫治疗相结合，促进肿瘤血管正常化，提高免疫治疗效率，是治疗乳腺癌的一种潜在的治疗策略。
Tumor angiogenesis induces local hypoxia and recruits immunosuppressive cells, whereas hypoxia subsequently promotes tumor angiogenesis. Immunotherapy efficacy depends on the accumulation and activity of tumor-infiltrating immune cells (TIICs). Antangiogenic therapy could improve local perfusion, relieve tumor microenvironment (TME) hypoxia, and reverse the immunosuppressive state. Combining antiangiogenic therapy with immunotherapy might represent a promising option for the treatment of breast cancer. This article discusses the immunosuppressive characteristics of the breast cancer TME and outlines the interaction between the tumor vasculature and the immune system. Combining antiangiogenic therapy with immunotherapy could interrupt abnormal tumor vasculature-immunosuppression crosstalk, increase effector immune cell infiltration, improve immunotherapy effectiveness, and reduce the risk of immune-related adverse events. In addition, we summarize the preclinical research and ongoing clinical research related to the combination of antiangiogenic therapy with immunotherapy, discuss the underlying mechanisms, and provide a view for future developments. The combination of antiangiogenic therapy and immunotherapy could be a potential therapeutic strategy for treatment of breast cancer to promote tumor vasculature normalization and increase the efficiency of immunotherapy.
登录
查看更多内容
DOI：
10.1158/1078-0432.ccr-20-1303
发表时间：
2020-10-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Ahmed FS;Gaule P;McGuire J;Patel K;Blenman K;Pusztai L;Rimm DL
通讯作者：
Rimm DL
影响因子：
7.3
作者：
Albini A;Bruno A;Noonan DM;Mortara L
通讯作者：
Mortara L
影响因子：
17.1
作者：
Allen E;Jabouille A;Rivera LB;Lodewijckx I;Missiaen R;Steri V;Feyen K;Tawney J;Hanahan D;Michael IP;Bergers G
通讯作者：
Bergers G
影响因子：
8
作者：
Castro BA;Flanigan P;Jahangiri A;Hoffman D;Chen W;Kuang R;De Lay M;Yagnik G;Wagner JR;Mascharak S;Sidorov M;Shrivastav S;Kohanbash G;Okada H;Aghi MK
通讯作者：
Aghi MK
影响因子：
168.9
作者：
Cortes, Javier;Cescon, David W.;Schmid, Peter
通讯作者：
Schmid, Peter